Skip to main content
Premium Trial:

Request an Annual Quote

Study Validates Analytical, Clinical Performance of Automated BG Medicine Galectin-3 Test


BG Medicine noted this week the publication of a study validating the analytical and clinical performance of an automated version of its BGM Galectin-3 heart failure test.

Published in Clinica Chimica Acta, the study used BioMérieux's VIDAS Galectin-3 assay, which the company has developed in partnership with BG, to analyze blood samples from 137 patients with chronic heart failure.

The study found that elevated galectin-3 levels as measured by the assay were predictive of fatal cardiovascular events and the severity of heart failure among these patients. It also found that the analytical performance of the automated assay matched that of the conventional, manual BGM Galectin-3 test.

In a statement, BG Medicine President and CEO Paul Sohmer said the results "support commercialization of the VIDAS Galectin-3 assay in Europe and substantiate our efforts to assist BioMérieux with its pursuit of [US Food and Drug Administration] 510(k) clearance of the assay in the US."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.